← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Convergent Genomics, Inc.
San Francisco, CA
$6,160,047
Total funding
1
Grants
Funding over time
peak $2.9M · FY2016–21$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,160,047 · 1
By mechanism
R44$6,160,047 · 1
Investigators at Convergent Genomics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Expanded Clinical Validation & Commercial Launch of the UriSeq Platform for Bladder Cancer$1,875,550
R44 · FY2020 · CA
Expanded Clinical Validation & Commercial Launch of the UriSeq Platform for Bladder Cancer$1,635,549
R44 · FY2021 · CA
Improved diagnostic sensitivity for rapid COVID-19 testing using Enhanced Preservation Media$999,975
R44 · FY2020 · CA
SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.$686,883
R44 · FY2017 · CA
SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.$670,314
R44 · FY2018 · CA
SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.$291,776
R44 · FY2016 · CA